Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more
Acumen Pharmaceuticals Inc (ABOS) - Total Liabilities
Latest total liabilities as of September 2025: $49.05 Million USD
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has total liabilities worth $49.05 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acumen Pharmaceuticals Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Acumen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Acumen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zimplats Holdings Limited
PINK:ZMPLF
|
USA | $1.24 Billion |
|
LH Financial Group Public Company Limited
BK:LHFG
|
Thailand | ฿356.09 Billion |
|
Hyundai Pharm
KO:004310
|
Korea | ₩85.40 Billion |
|
Datalogic S.p.A
OTCGREY:DLGCF
|
USA | $289.41 Million |
|
GKW Limited
NSE:GKWLIMITED
|
India | ₹6.13 Billion |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
USA | $24.04 Million |
|
Taaleri Oyj
HE:TAALA
|
Finland | €84.96 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Acumen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acumen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acumen Pharmaceuticals Inc (2019–2024)
The table below shows the annual total liabilities of Acumen Pharmaceuticals Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $57.18 Million | +32.50% |
| 2023-12-31 | $43.15 Million | +452.38% |
| 2022-12-31 | $7.81 Million | +51.78% |
| 2021-12-31 | $5.15 Million | -91.83% |
| 2020-12-31 | $63.02 Million | +236.25% |
| 2019-12-31 | $18.74 Million | -- |